

# ESMO PRECEPTORSHIP PROGRAMME

## COLORECTAL CANCER

Multidisciplinary management, standards of care  
and future perspectives

Valencia, Spain  
9-10 May 2025

### CO-CHAIRS

Andrés Cervantes, Spain  
Erika Martinelli, Italy

### SPEAKERS

Dimitri Dorcaratto, Spain  
Michel Ducreux, France  
Elena Élez, Spain  
Claire Gallois, France  
Carolina Martínez Ciarpaglini, Spain  
Dominik Modest, Germany

## LEARNING OBJECTIVES

- To learn about best clinical practice in the multidisciplinary management of colorectal cancer in the adjuvant and metastatic settings
- To understand the importance of pathology, histo- and moleculopathological prognostic factors
- To learn about sequencing of treatments, adverse events and special situations

## Friday, 9 May 2025

09:00-09:15 15'	Welcome and introduction	Andrés Cervantes, ES Erika Martinelli, IT
09:15-10:50 95'	<b>SESSION 1</b> Localised colon cancer – Part 1	<b>Chair:</b> Andrés Cervantes, ES
30'	Quality and rules of a good pathology report Histo- and moleculopathological biomarkers	Carolina Martínez Ciarpaglini, ES
30'	Adjuvant treatment for colon cancer stage II and III as standard of care	Michel Ducreux, FR
20'	Neoadjuvant chemotherapy for localised colon cancer as a potential option	Claire Gallois, FR
15'	Q&A	All
10:50-11:20	Coffee break	
11:20-12:30 70'	<b>SESSION 2</b> Localised colon cancer – Part 2	<b>Chair:</b> Erika Martinelli, IT
30'	Neoadjuvant immunotherapy for localised colorectal cancer: Facts and future prospective	Claire Gallois, France

10'	Q&A	All
30'	Participants clinical case discussion (3x10')	Faculty
<b>12:30-13:30</b>	<b>Lunch</b>	
<b>13:30-14:50 80'</b>	<b>SESSION 3 Current first-line treatment for metastatic colorectal cancer</b>	<b>Chair: Andrés Cervantes, ES</b>
40'	Recommendations according to ESMO guidelines: First-line strategy and specific subtypes	Erika Martinelli, IT
10'	Q&A	All
30'	Oligometastatic colorectal cancer: What to know about it and how to treat it	Dominik Modest, DE
<b>14:50-15:20</b>	<b>Coffee break</b>	
<b>15:20-17:20 120'</b>	<b>SESSION 4 Metastatic colorectal cancer: Special clinical situations</b>	<b>Chair: Andrés Cervantes, ES</b>
30'	How to integrate surgery in the treatment of patients with liver-only metastatic disease	Dimitri Dorcaratto, ES
45'	Presentation of three challenging clinical cases by the expert and faculty discussion	Dominik Modest, DE
15'	Q&A	All
30'	Participants clinical case discussion (3x10')	Faculty
<b>20:30</b>	<b>Dinner</b>	

## Saturday, 10 May 2025

<b>09:00-09:40 40'</b>	<b>SESSION 5 Localized rectal cancer</b>	<b>Chair: Erika Martinelli, IT</b>
30'	Standard of care of localised rectal cancer	Andrés Cervantes, ES
10'	Q&A	All
<b>09:40-11:55 105'</b>	<b>SESSION 6 Metastatic colorectal cancer: Maintenance and further lines</b>	<b>Chair: Andrés Cervantes, ES</b>
20'	What to do after first-line failure?	Elena Élez, ES
20'	Treating patients with chemorefractory disease: Challenges and opportunities	Dominik Modest, DE
30'	Management of treatment-related side effects: <ul style="list-style-type: none"> <li>- GI-toxicity</li> <li>- Neuropathy</li> <li>- Skin toxicity</li> </ul>	Michel Ducreux, FR

	<ul style="list-style-type: none"> <li>- Hypertension</li> <li>- Hand-foot syndrome</li> </ul>	
<b>10:50-11:20</b>	<b>Coffee break</b>	
20'	How to deal with patients with BRAF mutant, G12C mutant and HER2 amplified advanced colorectal cancer after first failure	Erika Martinelli, IT
15'	Q&A	All
<b>11:55-12:25 30'</b>	<b>SESSION 7 Metastatic colorectal cancer: Case discussion</b>	<b>Chair: Andrés Cervantes, ES</b>
30'	Participants clinical case discussion (3x10')	Faculty
<b>12:25-12:35 10'</b>	<b>Conclusion and farewell</b>	<b>Andrés Cervantes, ES Erika Martinelli, IT</b>
<b>12:35-13:35</b>	<b>Lunch</b>	

**Note:** Each 10-minute slot for clinical case discussion includes a 5' case presentation and a 5' Q&A / panel discussion